图书馆订阅: Guest
Begell Digital Portal Begell 数字图书馆 电子图书 期刊 参考文献及会议录 研究收集
医药载体系统评论综述
影响因子: 2.9 5年影响因子: 3.72 SJR: 0.736 SNIP: 0.551 CiteScore™: 2.43

ISSN 打印: 0743-4863
ISSN 在线: 2162-660X

医药载体系统评论综述

DOI: 10.1615/CritRevTherDrugCarrierSyst.v12.i2-3.10
pages 101-149

Approaches and Opportunities in Colon-Specific Drug Delivery

Abraham Rubinstein
Chairman, Department of Pharmaceutics, School of Pharmacy, Faculty of Medicine The Adolph Weinberger Building The Hebrew University, P.O. Box 12065 Jerusalem 91120, Israel

ABSTRACT

With the determination of the exact mode of action of sulfasalazine 20 years ago, attention and interest was drawn to the colonic delivery of drugs. A few years before that it became clear that some orally administered laxative drugs are active only after arrival at the large intestine. This resulted in research activity that led to the development of colonic dosage forms. Two major approaches were reported: (1) protective coats that bring the dosage form as close as possible to the colon after oral administration, (2) prodrugs, polymeric prodrugs, and biodegradable polymers that are degraded mostly by the unique enzymes of the colon. Usually, these enzymes are related to the normal colonic microflora. The new drug carriers were examined in vitro and in vivo (laboratory animals). Recently, an increasing number of studies suggest the use of polysaccharide hydrogels for oral delivery of colon-specific drug carriers.
Colonic delivery of drugs is associated with the local delivery of salicylate derivatives to the large intestine for the topical treatment of ulcerative colitis and sometimes the local treatment of irritable bowel syndrome. A common belief is that colonic delivery for orally administered protein drugs is possible because of the postulated low proteolysis activity in the large intestine, an assumption that requires further verification. Yet, other opportunities for colonic delivery of drugs also exist. Some recent examples include bypassing small intestine metabolism, achieving constant absorption rates for some molecules, and delivering cationized antioxidant enzymes to the colonic epithelium.
This article reviews the surge of research activity in the new area of colon-specific drug delivery systems and suggests some possible therapeutic opportunities in this field.


Articles with similar content:

Azo Chemistry and Its Potential for Colonic Delivery
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.23, 2006, issue 5
Yashwant Gupta, Anekant Jain, Sanjay Kumar Jain
Therapeutic Opportunities in Colon-Specific Drug-Delivery Systems
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.24, 2007, issue 2
Avani Amin, Mayur M. Patel, Tejal Shah
Pulsatile Drug-Delivery Systems
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.18, 2001, issue 5
Till Bussemer, Ina Otto, Roland Bodmeier
Nanostructured Lipid Carriers: A New Paradigm in Topical Delivery for Dermal and Transdermal Applications
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.34, 2017, issue 4
Gajanand Sharma, Bhupinder Singh, Kaisar Raza, Om Parkash Katare, Kanika Thakur
Factors Affecting Drug and Gene Delivery: Effects of Interaction with Blood Components
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.19, 2002, issue 3
Makiya Nishikawa, Mitsuru Hashida, Praneet Opanasopit